QTTB
Q32 Bio Inc
NASDAQ: QTTB · HEALTHCARE · BIOTECHNOLOGY
$5.18
+14.85% today
Updated 2026-06-04
Market cap
$218.23M
P/E ratio
4.28
P/S ratio
4.06x
EPS (TTM)
$3.01
Dividend yield
—
52W range
$1 – $15
Volume
0.8M
WallStSmart proprietary scores
54
out of 100
Grade: C
Hold
Investment rating
6.0
Growth
B7.0
Quality
B+10.0
Profitability
A+6.7
Valuation
B5/9
Piotroski F-Score
Moderate
-0.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$14.25
+175.10%
12-Month target
$7.26
+40.15%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 61.90% — above average
+ ROE 71.78% — strong efficiency
+ Debt/equity 0.29x — low leverage
Risks
- Altman Z -0.75 — distress zone
- Negative free cash flow $-6.34M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $6.65M | $-6.65M | $0.00 | $53.74M | $53.74M |
| Net income | $-42.81M | $-53.74M | $-47.73M | $29.82M | $-7.61M |
| EPS | — | — | — | — | $3.01 |
| Free cash flow | $-13.44M | $-18.68M | $-67.79M | $-33.55M | $-6.34M |
| Profit margin | -643.65% | 808.04% | — | 55.49% | 61.90% |
Peer comparison
Smart narrative
Q32 Bio Inc trades at $5.18. representing a P/E of 4.28x trailing earnings. Our Smart Value Score of 54/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -0.75, it sits in the distress. TTM revenue stands at $53.74M. with profit margins at 61.90%.
Frequently asked questions
What is Q32 Bio Inc's stock price?
Q32 Bio Inc (QTTB) trades at $5.18, on a P/E of 4.3x and a P/S of 4.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Q32 Bio Inc overvalued?
Q32 Bio Inc carries a Smart Value Score of 54/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Q32 Bio Inc (QTTB)?
The 12-month analyst consensus target is $14.25, about 175.1% above the current $5.18. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Q32 Bio Inc's revenue?
Q32 Bio Inc's trailing twelve-month revenue is $53.74M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Q32 Bio Inc's Altman Z-Score is -0.75, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.06x
ROE71.78%
Beta-0.23
50D MA$7.08
200D MA$4.31
Shares out0.02B
Float0.00B
Short ratio—
Avg volume0.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—